中文摘要：

目的：归纳硼替佐米在恶性血液病治疗中的应用进展。方法：对硼替佐米的结构性质、作用机制与其在恶性浆细胞病、非霍奇金淋巴瘤和白血病中的应用以及不良反应进行述评。结果与结论：蛋白酶体成为恶性血液病治疗中的重要靶点。硼替佐米在骨髓瘤的治疗中显示出独特优势,在白血病、恶性淋巴瘤等治疗中也取得了进展。以硼替佐米为核心的方案在治疗恶性血液病方面的疗效值得期待。

英文摘要：

OBJECTIVE： To summarize the application and development of bortezomib in the treatment of malignant hematono- sis. METHODS： The structure, property and mechanism of bortezomib, application of it in malignant plasma cell dyscrasias, non-Hodgkin lymphoma and leukocythemia as well as ADR were all reviewed. RESULTS＆CONCLUSIONS： Proteasomes is consid- ered as a target in malignant hematonosis therapy. Bortezomib shows unique advantage in myeloma therapy and completes some achievements in leukocythemia and lymphoma therapy, etc. Therapeutic efficacy of bortezomib-based malignant hematonosis thera- py plan will have been worth the waiting.